316 related articles for article (PubMed ID: 35848027)
1. Understanding the Involvement of microRNAs in Mitochondrial Dysfunction and Their Role as Potential Biomarkers and Therapeutic Targets in Parkinson's Disease.
Tryphena KP; Anuradha U; Kumar R; Rajan S; Srivastava S; Singh SB; Khatri DK
J Alzheimers Dis; 2023; 94(s1):S187-S202. PubMed ID: 35848027
[TBL] [Abstract][Full Text] [Related]
2. Involvement of miRNA on epigenetics landscape of Parkinson's disease: From pathogenesis to therapeutics.
Uppala SN; Tryphena KP; Naren P; Srivastava S; Singh SB; Khatri DK
Mech Ageing Dev; 2023 Jul; 213():111826. PubMed ID: 37268278
[TBL] [Abstract][Full Text] [Related]
3. Systemic Analysis of miRNAs in PD Stress Condition: miR-5701 Modulates Mitochondrial-Lysosomal Cross Talk to Regulate Neuronal Death.
Prajapati P; Sripada L; Singh K; Roy M; Bhatelia K; Dalwadi P; Singh R
Mol Neurobiol; 2018 Jun; 55(6):4689-4701. PubMed ID: 28710704
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial Dysfunction in Parkinson's Disease: New Mechanistic Insights and Therapeutic Perspectives.
Park JS; Davis RL; Sue CM
Curr Neurol Neurosci Rep; 2018 Apr; 18(5):21. PubMed ID: 29616350
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs, Parkinson's Disease, and Diabetes Mellitus.
Wang H
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799467
[TBL] [Abstract][Full Text] [Related]
6. MicroRNAs Dysregulation and Mitochondrial Dysfunction in Neurodegenerative Diseases.
Catanesi M; d'Angelo M; Tupone MG; Benedetti E; Giordano A; Castelli V; Cimini A
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825273
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease and microRNAs - Lessons from model organisms and human studies.
Evans B; Furlong HA; de Lencastre A
Exp Gerontol; 2021 Nov; 155():111585. PubMed ID: 34634413
[TBL] [Abstract][Full Text] [Related]
8. Modified level of miR-376a is associated with Parkinson's disease.
Baghi M; Rostamian Delavar M; Yadegari E; Peymani M; Pozo D; Hossein Nasr-Esfahani M; Ghaedi K
J Cell Mol Med; 2020 Feb; 24(4):2622-2634. PubMed ID: 31930701
[TBL] [Abstract][Full Text] [Related]
9. microRNAs in Parkinson's Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches.
Leggio L; Vivarelli S; L'Episcopo F; Tirolo C; Caniglia S; Testa N; Marchetti B; Iraci N
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29236052
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson's Disease and Multiple System Atrophy.
Marques TM; Kuiperij HB; Bruinsma IB; van Rumund A; Aerts MB; Esselink RAJ; Bloem BR; Verbeek MM
Mol Neurobiol; 2017 Dec; 54(10):7736-7745. PubMed ID: 27844283
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis.
Banerjee R; Starkov AA; Beal MF; Thomas B
Biochim Biophys Acta; 2009 Jul; 1792(7):651-63. PubMed ID: 19059336
[TBL] [Abstract][Full Text] [Related]
12. Expression characteristics of peripheral blood genes reveal potential biomarkers and candidate therapeutic targets for Parkinson's disease.
Chen W; Zhou D; Zhu N; Yan X; Jiang G; Zhao L
Cell Mol Biol (Noisy-le-grand); 2020 May; 66(2):118-124. PubMed ID: 32415937
[TBL] [Abstract][Full Text] [Related]
13. Dysregulated microRNAs in neural system: Implication in pathogenesis and biomarker development in Parkinson's disease.
Lu J; Xu Y; Quan Z; Chen Z; Sun Z; Qing H
Neuroscience; 2017 Dec; 365():70-82. PubMed ID: 28964753
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial Dysfunction and Parkinson's Disease: Pathogenesis and Therapeutic Strategies.
Moradi Vastegani S; Nasrolahi A; Ghaderi S; Belali R; Rashno M; Farzaneh M; Khoshnam SE
Neurochem Res; 2023 Aug; 48(8):2285-2308. PubMed ID: 36943668
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial dysfunction in Parkinson's disease.
Bose A; Beal MF
J Neurochem; 2016 Oct; 139 Suppl 1():216-231. PubMed ID: 27546335
[TBL] [Abstract][Full Text] [Related]
16. Transcriptomics and Proteomics Approach for the Identification of Altered Blood microRNAs and Plasma Proteins in Parkinson's Disease.
Yadav SK; Jauhari A; Singh N; Pandey A; Sarkar S; Pandey S; Garg RK; Parmar D; Yadav S
Cell Mol Neurobiol; 2023 Oct; 43(7):3527-3553. PubMed ID: 37219663
[TBL] [Abstract][Full Text] [Related]
17. Targeting epigenetic modifications in Parkinson's disease therapy.
Zhang D; Zhang J; Wang Y; Wang G; Tang P; Liu Y; Zhang Y; Ouyang L
Med Res Rev; 2023 Sep; 43(5):1748-1777. PubMed ID: 37119043
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial dysfunction-induced H3K27 hyperacetylation perturbs enhancers in Parkinson's disease.
Huang M; Lou D; Charli A; Kong D; Jin H; Zenitsky G; Anantharam V; Kanthasamy A; Wang Z; Kanthasamy AG
JCI Insight; 2021 Sep; 6(17):. PubMed ID: 34494552
[TBL] [Abstract][Full Text] [Related]
19. Targeting Mitochondria as a Therapeutic Approach for Parkinson's Disease.
Abrishamdar M; Jalali MS; Farbood Y
Cell Mol Neurobiol; 2023 May; 43(4):1499-1518. PubMed ID: 35951210
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA machinery in Parkinson's disease: a platform for neurodegenerative diseases.
Saghazadeh A; Rezaei N
Expert Rev Neurother; 2022 Jun; 22(6):427-453. PubMed ID: 26574782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
